$FDMT News
Last published 1d ago
- 1d agoFDMT4D Molecular Therapeutics (FDMT) - Guggenheim 3rd Annual Healthcare Innovation Conference - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsAll right. Welcome back to the Guggenheim Healthcare Innovation Conference. My name is Eddie Hickman, one of the biotech analysts here. I'm welcomed now by two members of the 4D Molecular Therapeutics team, CFO Christian
- 1w agoFDMT4DMT to Participate in Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 3w agoFDMT4D Molecular Therapeutics Investor Day 2026 - 4D MOLECULAR THERAPEUTICS INCEarnings Call Transcriptsyou you you Thank you. Thank you. Thank you. Thank you. We'll be right back. We'll be right back. We'll be right back. Thank you. Thank you. Thank you. Thank you for watching. We'll be right back. I'll see you next time.
- 3w agoFDMT4D Molecular Therapeutics Investor Day 2026 - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsHey guys, we're getting started. Thanks for all being here today. I'm sorry for those online. We're running a couple minutes late, but just want to make sure folks filtered in. My name is Julian Pei. I am the head of inv
- 3w agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 1mo agoFDMTMorgan Stanley 24th Annual Global Healthcare Conference - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsAll right, good afternoon, everybody. Welcome to this final session of day one of the Morgan Stanley Global Healthcare Conference. We're very excited to have the team from 4D here. Let me just start with a quick disclosu
- 1mo agoFDMT4D Molecular Therapeutics - 1773795 - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsAll right, good afternoon, everybody. Welcome to this final session of day one of the Morgan Stanley Global Healthcare Conference. We're very excited to have the team from 4D here. Let me just start with a quick disclosu
- 2mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 2mo agoFDMT4DMT to Participate in Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 2mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 3mo agoFDMT4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesGlobeNewswireCompleted enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027Presented positive 2-year data from 4D-150 PRISM Phase 2b at ASRS,
- 3mo agoFDMT4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD PopulationGlobeNewswireAfter a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated with no new
- 3mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 4mo agoFDMT4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina SpecialistsGlobeNewswireEMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 4mo agoFDMT4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMDGlobeNewswire4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest
- 4mo agoFDMTHTGC4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules CapitalGlobeNewswireEMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 4mo agoVANIFDMTVivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean BakerGlobeNewswireALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
- 5mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 5mo agoFDMTGoldman Sachs 47th Annual Global Healthcare Conference - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsOkay, well, thank you everyone for joining us. We are here with FDMT, Christian Humer, CFO, and Chris Simms, CCO, and CVO. Maybe you could start with an overview of your directed evolution gene therapy platform, your pip
- 5mo agoFDMTGoldman Sachs 47th Annual Global Healthcare Conference - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsOkay, well, thank you everyone for joining us. We are here with FDMT, Christian Humer, CFO, and Chris Simms, CCO, and CVO. Maybe you could start with an overview of your directed evolution gene therapy platform, your pip
- 5mo agoFDMTJefferies Global Healthcare Conference in New York - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsAll right, good afternoon, everyone. Thank you to those of you in the room and those dialed in on the webcast. My name is Faisal Khurshid. I'm one of the senior biotech analysts here at Jefferies. I'm really pleased to h
- 5mo agoFDMT4DMT to Participate in Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 6mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 6mo agoFDMT4D Molecular Therapeutics Inc at 2026 Global Healthcare Conference - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsHi, everyone. Welcome back to the Bank of America Healthcare Conference. My name is Daniel Giraldo. I'm one of the biotech analysts here at B of A. Our next presenting company is 4D Molecular Therapeutics. Some members f
- 6mo agoFDMT4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesGlobeNewswire4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 4FRONT-2 enrollment completion expected in H2 2026; topline data expected in H2 2027 4D-150 PRISM wet AMD Phase 2b 2-year
- 6mo agoFDMT4DMT to Participate in Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 6mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 8mo agoFDMT4DMT to Participate in Upcoming Investor MeetingsGlobeNewswireEMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 8mo agoFDMTBarclays 28th Annual Global Healthcare Conference - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsHi, good morning, everyone. I'm Ellie Murrell, one of the biotech analysts here at Barclays. Thank you for joining us here in sunny Miami. I'm very happy to have 4D Molecular Therapeutics here with us today for a firesid
- 8mo agoFDMTTD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsGood morning everyone. I appreciate the time to share with you an overview of 4D molecular therapeutics. So we'll walk through today how 4DMT, we believe, is well positioned to redefine genetic medicines for millions of
- 8mo agoFDMT4DMT to Participate in Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 9mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 9mo agoFDMT4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMDGlobeNewswireEnrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients
- 9mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 10mo agoFDMT4DMT Provides Company Update and Anticipated Development Milestones for 2026GlobeNewswireEnrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6,
- 10mo agoFDMTAEROW Phase 1 Interim Data for 4D-710 in Cystic Fibrosis - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsHello, ladies and gentlemen, thank you for standing by and welcome to our investor webcast today. As a reminder, today's call is being recorded. With that, I will hand the call over to Julian Pye, Head of Investor Relati
- 10mo agoFDMTAEROW PHASE 1 INTERIM DATA FOR 4D-710 IN CYSTIC FIBROSIS - 4D MOLECULAR THERAPEUTICS INCEarnings Call TranscriptsHello, ladies and gentlemen, thank you for standing by and welcome to our investor webcast today. As a reminder, today's call is being recorded. With that, I will hand the call over to Julian Pye, Head of Investor Relati
- 10mo agoFDMT4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung DiseaseGlobeNewswireClinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up
- 11mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 11mo agoFDMT4DMT to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 11mo agoAURAFDMTNBPNovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 ForwardGlobeNewswireCadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract
- 11mo agoFDMT4DMT to Participate in 8th Annual Evercore Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 11mo agoFDMT4DMT Appoints Kristian Humer as Chief Financial OfficerGlobeNewswireEMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 12mo agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 1y agoFDMT4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesGlobeNewswireEntered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50
- 1y agoFDMT4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireEMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 1y agoFDMT4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple YearsGlobeNewswire4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up to
- 1y agoFDMT4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-PacificGlobeNewswire4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336
- 1y agoFDMT4DMT Announces New Employment Inducement GrantsGlobeNewswireEMERYVILLE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with
- 1y agoFDMT4DMT to Participate in Chardan's 9th Annual Genetic Medicines ConferenceGlobeNewswireEMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with